NeXT Personal Dx - Personalis Powered to see MRD that previously avoided detection 1-6 NeXT Personal® Dx is a tumor-informed molecular residual disease (MRD) liquid biopsy with ultra-high sensitivity and sp
Careers in Precision Oncology - Personalis We’re looking for team members who are driven to advance the field of precision oncology Together, we can transform the future of cancer care
Personalis and Tempus Announce Expanded Collaboration | Personalis Tempus is serving as exclusive commercial partner for Personalis’ ultra-sensitive tumor-informed MRD product for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors